Key Performance
More- Earnings Score: N/A
- Momentum Score: 61
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million from $25.3 million year-over-year due to reduced manufacturing and CRO costs following ALTITUDE-AD enrollment completion.
05/12/2026, 7:00 AM • GlobeNewswire
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is advancing its lead candidate sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers, in its Phase 2 ALTITUDE-AD trial for early symptomatic Alzheimer's disease, with topline results expected in late 2026.
05/07/2026, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Acumen Pharmaceuticals announced it will report first quarter 2026 financial results on May 12, 2026, with a conference call and webcast at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, with topline results from the Phase 2 ALTITUDE-AD trial expected in late 2026.
05/05/2026, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.
03/19/2026, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials following positive Phase 1 results.
03/10/2026, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.
11/05/2025, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.
08/26/2025, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals will report Q2 2025 financial results on August 12, 2025, and host a conference call to provide a business and financial update, focusing on their Alzheimer's disease therapeutic candidate sabirnetug.
08/05/2025, 4:00 PM • GlobeNewswire
Acumen Pharmaceuticals will present research on cost savings and drug selectivity for sabirnetug, a potential Alzheimer's disease treatment, at the Alzheimer's Association International Conference in Toronto in July 2025.
07/10/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.